Match tier Listed
Presence Current · Arkansas
Last published 2026
Sources OpenAlex · ORCID
Refreshed 2026-10-05

Behjatolah Monzavi‐Karbassi

Federal Grant PI High Impact

Associate Professor

Also affiliated: Russian Academy of Sciences (1998); University of Arkansas Medical Center (2005–2016); Institute of Molecular Genetics (1998); University of Pennsylvania (1999–2003)

24 h-index 79 pubs 1,627 cited

  • Humans
  • Animals
  • Mice
  • Molecular Mimicry
  • Female
  • Mice, Inbred BALB C
  • Peptides
  • Antigens, Tumor-Associated, Carbohydrate
  • Carbohydrates
  • Breast Neoplasms
  • Cancer Vaccines
  • Amino Acid Sequence
  • Molecular Sequence Data
  • Cross Reactions
  • Neoplasms

Biography and Research Information

OverviewAI-generated summary

Behjatolah Monzavi‐Karbassi's research focuses on tumor-associated carbohydrate antigens and their role in cancer, particularly breast cancer metastasis. His work investigates how molecules like chondroitin sulfates contribute to aggressive cancer cell phenotypes and the formation of P-selectin ligands, which are implicated in cancer cell adhesion and spread. He has also explored the potential of peptide mimotopes as surrogate antigens for carbohydrate targets in vaccine development, aiming to elicit functional antibody responses against tumor-associated carbohydrates.

Monzavi‐Karbassi is the Principal Investigator on a National Cancer Institute grant totaling $178,819, studying "SR-A as a therapeutic target in breast cancer." His publications include work on the immune surveillance of tumor-associated glycans and the induction of anti-carbohydrate antibodies through DNA immunization with carbohydrate mimotopes. He has also investigated the metabolic influence of fructose on breast tumor cell aggression. His scholarship metrics include an h-index of 24, with 78 total publications and 1,627 total citations, designating him as a highly cited researcher.

Metrics

  • h-index: 24
  • Publications: 79
  • Citations: 1,627

Positions

  • Associate Professor publications 2003–2026
    University of Arkansas for Medical Sciences Pathology ORCID

Selected Publications

  • Class A scavenger receptors promote tumor progression and induce a unique macrophage phenotype in a mouse model of spontaneous breast cancer (2026)
    Journal of Leukocyte Biology DOI OpenAlex
  • Abstract PO5-02-05: Assessing Vaccine-Mediated Cellular Immune Responses in Patients Receiving Combined Vaccine and Chemotherapy Treatment (2024)
    Cancer Research DOI OpenAlex
  • Abstract 3860: Characterizing peripheral immune correlates of tumor response in breast cancer patients immunized with the P10s-PADRE vaccine (2024)
    Cancer Research DOI OpenAlex
  • Abstract 186: Tumor exosome-macrophage interactions: The role of tumor-associated glycans and scavenger receptor class A (2024)
    Cancer Research DOI OpenAlex
  • The Tumor Microenvironment and Immune Response in Breast Cancer (2024)
    International Journal of Molecular Sciences 2 citations DOI OpenAlex
  • Abstract 700: Induction of cancer-specific T-cell responses in patients immunized with P10s-PADRE vaccine (2023)
    Cancer Research DOI OpenAlex
  • Feeding Soy Protein Concentrates with Low and High Isoflavones Alters 9 and 18 Weeks Serum Isoflavones and Inflammatory Protein Levels in Lean and Obese Zucker Rats (2023)
    Journal of Medicinal Food 9 citations DOI OpenAlex
  • VT68.2: An Antibody to Chondroitin Sulfate Proteoglycan 4 (CSPG4) Displays Reactivity against a Tumor-Associated Carbohydrate Antigen (2023)
    International Journal of Molecular Sciences 3 citations DOI OpenAlex
  • Feeding Obese Zucker Rats With Soy Protein Concentrate With High Isoflavones Compared to Low Isoflavones Leads to a Significant Reduction of Serum Tumor Necrosis Factor-α (2022)
    Current Developments in Nutrition DOI OpenAlex
  • Abstract P2-14-15: Timing of the immunization defines immune signature of a peptide cancer vaccine combined with Neoadjuvant chemotherapy in HR+ breast cancer patients (2022)
    Cancer Research DOI OpenAlex
  • P10s-PADRE vaccine combined with neoadjuvant chemotherapy in ER-positive breast cancer patients induces humoral and cellular immune responses (2021)
    Oncotarget 11 citations DOI OpenAlex
  • Association of DNA-Methylation Profiles With Immune Responses Elicited in Breast Cancer Patients Immunized With a Carbohydrate-Mimicking Peptide: A Pilot Study (2020)
    Frontiers in Oncology 2 citations DOI OpenAlex
  • Carbohydrate (Chondroitin 4) Sulfotransferase-11-Mediated Induction of Epithelial-Mesenchymal Transition and Generation of Cancer Stem Cells (2020)
    Pharmacology 10 citations DOI OpenAlex
  • Macrophage Class A Scavenger Receptors Bind Tumor‐Associated Carbohydrate Antigens and Promote Breast Cancer Growth and Metastases in Mice (2020)
    The FASEB Journal DOI OpenAlex
  • Abstract P3-09-18: Immunization of breast cancer patients in combination with standard-of-care chemotherapy: Results of a phase Ib clinical trial (2020)
    Cancer Research DOI OpenAlex

View all publications on OpenAlex →

Federal Grants 1 $178,819 total

NIH Contact PI Jan 2024 - Dec 2026

SR-A as a therapeutic target in breast cancer

National Cancer Institute $178,819 R21

Collaboration Network

110 Collaborators 33 Institutions 6 Countries

Top Collaborators

View profile →
View profile →
View profile →
View profile →
View profile →
View profile →

Similar Researchers

Based on overlapping research topics